Dispensing of GLP-1 receptor agonists increased nearly 600% among adolescents and young adults in the United States from 2020 to 2023 and was particularly significant among girls and young women, a new study showed.According to Joyce M. Lee, MD, MPH, a professor of pediatrics and communicable diseases at the University of Michigan School of Public Health, and colleagues, interest in GLP-1